Invest in ME statement (April 2013 Newsletter):
http://www.investinme.org/IIME-Newslet-1304-01.htm
In the UK two collaborative meetings for ME research are planned.
Soon the Science Media Centre and Professor Stephen Holgate and Dr Esther Crawley will host an afternoon event to publicise a "research collaborative" for CFS -
UK CFS/ME Collaborative. We shall refer to this as the SMC collaborative. This event on 22nd April will be organised by the Science Media Centre in London.
One month later, in London, Invest in ME and the Alison Hunter Memorial Foundation will convene a Biomedical Research into ME Colloquium 3 (BRMEC3) - click here. Invited will be biomedical researchers from seven countries.
The SMC event apparently follows on from the MRC CFS/ME panel which was disbanded after three years, having held just a handful of meetings.
Invest in ME has been invited to attend - due to the research which the charity has proposed and funded - and, along with other invitees, the charity received an email from Dr Crawley and Professor Holgate containing information about the SMC event.
The chair of the SMC collaborative will be Professor Holgate - the deputy chair will be Dr Esther Crawley. Charities such as AfME, MEA, AYME and MER UK will have been involved in the planning with Professor Holgate and Dr Crawley.
The invitation to the SMC event sent by Dr Crawley to invitees states -
"In addition to joining forces for raising the profile of research and prioritising key areas for research, a UK CFS/ME Research Collaborative could look to jointly fund projects, capacity building (especially through involvement of those not currently engaged in the field and looking to support young scientists), encouraging targeted fund raising as well as galvanising some clear directions of travel in the field."
These seem like creditable objectives.
Yet on closer examination one finds that included in this SMC collaborative there will also be many of those who believe ME is a somatoform disorder. Included will be those behind the PACE Trial, the SMILE study etc.
So the question might be posed exactly what are the "
..clear directions of travel in the field" for this SMC collaborative to which Dr Crawley refers?
"For many years two opposing views of ME have been maintained - whether for genuine reasons or for political and financial expediency. This has pitted patients against establishment organisations who deny this disease as real or of organic origin."
Professor Holgate's reasoning behind this SMC collaborative is that -
"a similar collaborative, as well as an MRC Highlight Notice, has helped to increasing MRC, Industry and Charity investment into respiratory disease 4-fold over the last 5 years when it was recognised that more needed to be done in this field".
and
"Two key principles for the success of this (respiratory research) has been a willingness to join forces, support of ALL types of research and ensuring high quality as judged by robust peer review."
We have stated before that it will be interesting to know how this can be achieved.
The problem with transposing a model of research for respiratory disease onto the ME landscape is, of course, that respiratory disease is a universally accepted disease and is not questioned by an influential and controlling ideology that continues to describe and treat ME as a behavioural illness and refuses to accept that it is of organic origin.
For many years two opposing views of ME have been maintained - whether for genuine reasons or for political and financial expediency. This has pitted patients against establishment organisations who deny this disease as real or of organic origin.
To discard the politics and machinations that have gone on for a generation with regard to this disease is certainly something we can understand might be convenient - we have to move on from the past.
Yet the past cannot be completely ignored if one is truly intent on building a force for change and progress which includes people who still hold ME to be a behavioural illness. A great deal of re-invention of their positions by some leading figures would need to be made before one can really believe such a strategy would work.
The MRC CFS/ME panel achieved little when compared to the amount of time it was meant to be active. More importantly three more valuable years of opportunity were lost.
The problems and issues which the MRC panel really should have resolved have not been addressed - instead a void remains where these elements for a sensible and scientific strategy for research should have been agreed.
An example is the lack of agreement (or even discussion ?) regarding a standard diagnostic criteria set to define ME and differentiate from Chronic Fatigue.
Only the Canadian Consensus Criteria and International Criteria accurately describe the symptoms of ME and therefore should be the only ones used. Psychiatrists who purport to study ME use the Oxford Criteria which simply describes fatigue. An illness cannot be studied unless it is accurately defined.
After three years of existence of the MRC CFS/ME panel only a comparatively small amount of funding was awarded for research which either did not cover ME or was not related to establishment of causality. The current highlight notice from the MRC [
2] is more promising, if the right type of researchers apply and get funding.
Another questionable area in this new MRC/SMC collaborative will be the requirement for anyone participating to agree to support and fund "
ALL research into CFS/ME including fatigue".
The only way any organisation can be included in this SMC collaborative is to sign up to a charter created by Professor Holgate, Dr Crawley and presumably the four charities who have already been instrumental in creation of this charter and can then drive it. The letter from Dr Crawley includes the comment that the charter -
"will lay out the terms for membership that will strongly emphasise the need for
ALL types of high quality research (into CFS) and a joined-up approach to deliver this", including fatigue.
The full contents of this charter - though known to some - will not be revealed until that April 22nd meeting.
We have written in the past that we feel
it is impossible to marry the views of those who believe in the deconditioning/behavioural and wrong illness belief model of ME with those from the biomedical side. The failed PACE Trial has demonstrably proven that the behavioural view of ME cannot deliver and should not continue to command more funding.
This naturally leads to many questions about this MRC/SMC collaborative and its proposed method of working. The composition of the MRC/SMC collaborative includes polarised views of ME so is it really possible, or wise, to try to marry these widely differing views together? Why is a charter actually required that all must sign up to, as indicated by Dr Crawley?
Will the mandatory charter reject or remove those who disagree with the psychosocial side of the MRC/SMC collaborative? Who will peer-review applications for funding from biomedical researchers? What cohorts of patients will participate in research and what diagnostic criteria will be used? Will funding generated by this MRC/SMC collaborative be used to create a strategy of biomedical research? Why is fatigue necessary to be mentioned in the handouts?
These are questions which will hopefully be answered.